-
1.发明公开
公开(公告)号：EP2094709A1
公开(公告)日：2009-09-02
申请号：EP07842582.4
申请日：2007-09-17
发明人： CHEN, Zhaogen , HAMDOUCHI, Chafiq, Hamdouchi , HEMBRE, Erik, James , HIPSKIND, Philip, Arthur , MYERS, Jason, Kenneth , TAKAKUWA, Takako , TOTH, James, Lee
IPC分类号： C07D487/04 , A61K31/505 , A61P29/00 , A61P25/22 , A61P25/24 , A61P25/30
CPC分类号： C07D487/04
摘要： The present invention relates to compounds of Formula (I), pharmaceutical compositions thereof, and use thereof as corticotropin releasing factor 1 (CRF1) receptor antagonists in the treatment of psychiatric and neuroendocrine disorders, neurological diseases, and metabolic syndrome.
-
公开(公告)号：EP1861360B1
公开(公告)日：2009-12-02
申请号：EP06738050.1
申请日：2006-03-13
发明人： BEAVERS, Lisa, Selsam , FINLEY, Don, Richard , GADSKI, Robert, Alan , HIPSKIND, Philip, Arthur , JESUDASON, Cynthia, Darshini , PICKARD, Richard, Todd , STEVENS, Freddie, Craig , TAKAKUWA, Takako
IPC分类号： C07D207/09 , C07D401/14 , A61K31/40 , A61K31/435 , A61P25/00
CPC分类号： C07D207/09 , C07D401/14
摘要： The present invention discloses novel compounds of Formula (I) or pharmaceutically acceptable salts thereof which have histamine-H3 receptor antagonist or inverse agonist activity, as well as methods and intermediates for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula (I) as well as methods of using them to treat obesity, cognitive deficiencies, narcolepsy, and other histamine H3 receptor-related diseases.
-
3.发明公开NON-IMIDAZOLE ARYL ALKYLAMINES COMPOUNDS AS HISTAMINE H3 RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES 审中-公开非咪唑阿魏酸亚苄基维生素ALS组胺素H3抗抑郁药，HERSTELLUNG UND PHARMAZEUTISCHE VERWENDUNGEN
公开(公告)号：EP1379493A2
公开(公告)日：2004-01-14
申请号：EP02723329.5
申请日：2002-03-21
发明人： BEAVERS, Lisa, Selsam , GADSKI, Robert, Alan , HIPSKIND, Philip, Arthur , LINDSLEY, Craig, William , LOBB, Karen, Lynn , NIXON, James, Arthur , PICKARD, Richard, Todd , SCHAUS, John, Mehnert , TAKAKUWA, Takako , WATSON, Brian, Morgan
IPC分类号： C07C217/58 , A61K31/395 , A61K31/131 , A61P3/00 , A61P25/00 , C07D295/08 , C07D295/12 , C07C217/20 , C07C311/05 , C07C311/13 , C07C311/18 , C07C237/08 , C07D295/14 , C07C217/74 , C07C271/34 , C07C323/62 , C07C271/24 , C07C233/73 , C07C237/32 , C07C311/17 , C07C409/12
CPC分类号： C07D207/27 , C07B2200/07 , C07C217/20 , C07C217/58 , C07C217/74 , C07C233/73 , C07C237/08 , C07C237/32 , C07C271/24 , C07C271/34 , C07C311/05 , C07C311/09 , C07C311/11 , C07C311/18 , C07C2601/02 , C07C2601/14 , C07C2602/10 , C07D207/09 , C07D207/14 , C07D207/16 , C07D211/22 , C07D211/26 , C07D213/38 , C07D215/20 , C07D217/06 , C07D217/08 , C07D217/24 , C07D231/04 , C07D231/12 , C07D233/36 , C07D233/56 , C07D235/14 , C07D241/44 , C07D243/08 , C07D249/08 , C07D295/088 , C07D295/096 , C07D295/13 , C07D295/15 , C07D307/12 , C07D307/14 , C07D307/46 , C07D333/34 , C07D401/06 , C07D409/06 , C07D409/12 , C07D413/06 , C07D417/06 , C07D487/04
摘要： The present invention discloses novel substituted aryl alkylamine compounds of Formula (I) or pharmaceutically acceptable salts thereofwhich have selective histamine-H3 receptor antagonist activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such cyclic amines as well as methods of using them to treat obesity and other histamine H3 receptor -related diseases.
摘要翻译： 本发明公开了具有选择性组胺-H 3受体拮抗剂活性的式（I）的新型取代芳基烷基胺化合物或其药学上可接受的盐以及其制备方法。 在另一个实施方案中，本发明公开了包含这种环胺的药物组合物以及使用它们治疗肥胖症和其他组胺H3受体相关疾病的方法。
-
公开(公告)号：EP1904442A1
公开(公告)日：2008-04-02
申请号：EP06774260.1
申请日：2006-06-28
发明人： BEAVERS, Lisa, Selsam , FINLEY, Don, Richard , GADSKI, Robert, Alan , HIPSKIND, Philip, Arthur , HORNBACK, William, Joseph , JESUDASON, Cynthia, Darshini , PICKARD, Richard, Todd , TAKAKUWA, Takako , VAUGHT, Grant, Mathews
IPC分类号： C07D207/09 , C07D403/12 , C07D401/12 , A61K31/4025 , A61P3/04 , A61P25/28
CPC分类号： C07D207/09 , C07D401/12 , C07D403/12
摘要： The present invention discloses novel compounds of Formula I or pharmaceutically acceptable salts thereof which have histamine-H3 receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I as well as methods of using them to treat obesity, cognitive deficiencies, narcolepsy, and other histamine H3 receptor-related diseases. (Formula I)
-
公开(公告)号：EP1869049A1
公开(公告)日：2007-12-26
申请号：EP06738924.7
申请日：2006-03-20
发明人： BARBOSA, Heather, Janelle , COLLINS, Elizabeth, Aaron , HAMDOUCHI, Chafiq , HEMBRE, Erik, James , HIPSKIND, Philip, Arthur , JOHNSTON, Richard, Duane , LU, Jianliang , RUPP, Michael, John , TAKAKUWA, Takako , THOMPSON, Richard, Craig
IPC分类号： C07D487/04 , A61K31/5025 , A61P25/20
CPC分类号： C07D487/04
摘要： The present invention relates to novel substituted imidazo[1,2-b]pyridazine compounds of Formula (I): pharmaceutical compositions thereof, and the use such compounds as corticotropin releasing factor 1 (CRF1) receptor antagonists in the treatment of psychiatric disorders and neurological diseases.
-
公开(公告)号：EP1784400A1
公开(公告)日：2007-05-16
申请号：EP05789881.9
申请日：2005-08-15
发明人： FINLEY, Don, Richard , FINN, Terry, Patrick , HIPSKIND, Philip, Arthur , HORNBACK, William, Joseph , JESUDASON, Cynthia, Darshini , TAKAKUWA, Takako
IPC分类号： C07D409/10 , C07D413/14 , C07D409/14 , C07D417/10 , C07D405/10 , C07D403/10 , C07D401/14 , C07D417/14 , A61K31/4025 , A61P25/00
CPC分类号： C07D207/327 , C07D401/14 , C07D403/10 , C07D405/10 , C07D409/10 , C07D409/14 , C07D413/14 , C07D417/10 , C07D417/14
摘要： The present invention provides a novel compound of Formula (I) or a pharmaceutically acceptable salt thereof, having histamine-H3 receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds. In another, embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula (I) as well as methods of using them to treat obesity, cognitive deficiencies, narcolepsy, and other histamine H3 receptor-related diseases.
摘要翻译： 本发明提供了具有组胺-H3受体拮抗剂或反向激动剂活性的式（I）的新型化合物或其药学上可接受的盐，以及制备该化合物的方法。 在另一个实施方案中，本发明公开了包含式（I）化合物的药物组合物以及使用它们治疗肥胖症，认知缺陷，嗜睡症和其他组胺H3受体相关疾病的方法。
-
公开(公告)号：EP1879896A1
公开(公告)日：2008-01-23
申请号：EP06740278.4
申请日：2006-04-03
发明人： COLLINS, Elizabeth, Aaron , GARCIA-LOSADA, Pablo , HAMDOUCHI, Chafiq , HIPSKIND, Philip, Arthur , LU, Jianliang , TAKAKUWA, Takako
IPC分类号： C07D487/04 , A61K31/5025 , A61P25/20
CPC分类号： C07D487/04
摘要： The present invention relates to novel substituted imidazo[1,2-b] pyridazine compounds of Formula (I) pharmaceutical compositions thereof, and the use such compounds as corticotropin releasing factor 1 (CRF1) receptor antagonists in the treatment of psychiatric disorders and neurological diseases.
摘要翻译： 本发明涉及式（I）的新型取代的咪唑并[1,2-b]哒嗪化合物及其药物组合物，以及该化合物如促肾上腺皮质激素释放因子1（CRF1）受体拮抗剂在治疗精神病和神经疾病中的用途 。
-
公开(公告)号：EP1868991A1
公开(公告)日：2007-12-26
申请号：EP06758217.1
申请日：2006-03-28
发明人： HIPSKIND, Philip, Arthur , TAKAKUWA, Takako , JESUDASON, Cynthia, Darshini , GADSKI, Robert, Alan , HORNBACK, William, Joseph , PICKARD, Richard, Todd , BEAVERS, Lisa, Selsam
IPC分类号： C07D207/09 , C07D401/06 , A61K31/4025 , A61P3/04
CPC分类号： C07D207/09 , C07D401/06
摘要： The present invention discloses novel compounds of Formula (I) or pharmaceutically acceptable salts thereof which have histamine-H3 receptor antagonist or inverse agonist activity, as well as methods and intermediates for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula (I) as well as methods of using these compositions to treat obesity, cognitive deficiencies, narcolepsy, and other histamine H3 receptor-related diseases.
-
公开(公告)号：EP1861360A1
公开(公告)日：2007-12-05
申请号：EP06738050.1
申请日：2006-03-13
发明人： BEAVERS, Lisa, Selsam , FINLEY, Don, Richard , STEVENS, Freddie, Craig , PICKARD, Richard, Todd , JESUDASON, Cynthia, Darshini , HIPSKIND, Philip, Arthur , GADSKI, Robert, Alan , TAKAKUWA, Takako
IPC分类号： C07D207/09 , C07D401/14 , A61K31/40 , A61K31/435 , A61P25/00
CPC分类号： C07D207/09 , C07D401/14
摘要： The present invention discloses novel compounds of Formula (I) or pharmaceutically acceptable salts thereof which have histamine-H3 receptor antagonist or inverse agonist activity, as well as methods and intermediates for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula (I) as well as methods of using them to treat obesity, cognitive deficiencies, narcolepsy, and other histamine H3 receptor-related diseases.
-
公开(公告)号：EP1735278A1
公开(公告)日：2006-12-27
申请号：EP05730691.2
申请日：2005-03-25
发明人： BEAVERS, Lisa, Selsam , FINLEY, Don, Richard , FINN, Terry, Patrick Eli Lilly and Company , GADSKI, Robert, Alan , HIPSKIND, Philip, Arthur , HORNBACK, William, Joseph , JESUDASON, Cynthia, Darshini , PICKARD, Richard, Todd , TAKAKUWA, Takako , VAUGHT, Grant, Mathews
IPC分类号： C07D207/09 , C07D401/10 , C07D413/10 , C07D403/10 , C07D405/10 , A61K31/00 , A61K31/4025 , A61P25/00 , A61P3/04
CPC分类号： C07D207/09 , C07D401/10 , C07D403/10 , C07D405/10 , C07D413/10 , C07D471/04
摘要： The present invention discloses novel compounds of Formula (I) or pharmaceutically acceptable salts thereof, which have histamine-H3 receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula (I) as well as methods of using them to treat obesity, cognitive deficiencies, narcolepsy, and other histamine H3 receptor-related diseases
-
-
-
-
-
-
-
-
-
搜索结果
16 条记录 (耗时 0.022 秒)
